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Bile acid (BA) receptors represent well-defined targets for the development of novel
therapeutic approaches to metabolic and inflammatory diseases. In the present study,
we report the generation of novel C-3 modified 6-ethylcholane derivatives. The
pharmacological characterization and molecular docking studies for the structure-
activity rationalization, allowed the identification of 3β-azido-6α-ethyl-7α-hydroxy-
5β-cholan-24-oic acid (compound 2), a potent and selective FXR agonist with a
nanomolar potency in transactivation assay and high efficacy in the recruitment of
SRC-1 co-activator peptide in Alfa Screen assay. In vitro, compound 2 was completely
inactive towards common off-targets such as the nuclear receptors PPARα, PPARγ,
LXRα, and LXRβ and the membrane G-coupled BA receptor, GPBAR1. This compound
when administered in vivo exerts a robust FXR agonistic activity increasing the liver
expression of FXR-target genes including SHP, BSEP, OSTα, and FGF21, while
represses the expression of CYP7A1 gene that is negatively regulated by FXR.
Collectively these effects result in a significant reshaping of BA pool in mouse. In
summary, compound 2 represents a promising candidate for drug development in liver
and metabolic disorders.
Keywords: bile acids, bile acid receptors, farnesoid X receptor, drug discovery, liver-disorders, cholestasis,
fibrosis
INTRODUCTION
Bile acids (BAs), the end products of cholesterol metabolism, are increasingly recognized for their
role as signaling molecules. The signaling pathways involve the interaction with several nuclear
receptors (NRs) and cell surface G-protein-coupled receptors (G-PCRs), including the G protein-
coupled bile acid receptor GPBAR1 (also known as TGR5 or M-BAR) (Maruyama et al., 2002;
Kawamata et al., 2003; Fiorucci and Distrutti, 2015; Copple and Li, 2016). Among NRs, the
farnesoid X receptor (FXR) (Makishima et al., 1999; Parks et al., 1999; Wang et al., 1999) is the
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master gene that orchestrates BA homeostasis. Upon BA binding,
FXR regulates a network of genes in synthesis, uptake, and
secretion along with intestinal absorption, thus regulating the
level of BAs in the cells (Goodwin et al., 2000). An abnormal
BA metabolism associates with liver injury, metabolic disorders,
cardiovascular and digestive system diseases (Fiorucci and
Baldelli, 2009; Fiorucci et al., 2010b, 2014; Sepe et al., 2015a).
In addition, FXR plays a crucial beneficial role in triglyceride
and cholesterol homeostasis, as well as in glucose metabolism
(Fiorucci et al., 2004, 2007, 2009, 2010a,c; Cariou et al., 2006;
Zhang et al., 2006; Cipriani et al., 2010; Mencarelli et al., 2013;
Swanson et al., 2013).
As a consequence, FXR ligands have been claimed as new
therapeutical options in a wide range of diseases related
to metabolic, inflammatory and immune-modulated disorders
including type II diabetes, primary biliary cirrhosis (PBC),
nonalcoholic fatty liver disease (NAFLD), and nonalcoholic
steatohepatitis (NASH) (Fiorucci and Baldelli, 2009; Fiorucci
et al., 2011b, 2012a,b, 2014; Sepe et al., 2015a).
On the other hand, GPBAR1 activation exerts useful
pharmacological effects such as increased energy expenditure by
brown and white adipose tissue, glucagon-like peptide 1 (GLP-1)
secretion by intestinal endocrine cells which hold the potential for
beneficial effects on glucose metabolism and insulin sensitivity
(vanNierop et al., 2017; Hodge and Nunez, 2016).
Collectively, these findings have prompted the development
of dual GPBAR1/FXR agonists as a new frontier in
the pharmacological treatment of hypercholesterolemia,
hypertriglyceridemia, and type II diabetes (Fiorucci et al., 2009;
Fiorucci and Distrutti, 2015; Sepe et al., 2015b). However, the
concomitant activation of GPBAR1 associates with potential
side effects, including itching (Alemi et al., 2013; Lieu et al.,
2014), cholesterol gallstone formation (Vassileva et al., 2006) and
gallbladder overfilling (Li et al., 2011). Therefore, the discovery of
highly selective FXR agonists, devoid of GPBAR1 agonist activity,
is therapeutically attractive for the treatment of conditions where
the concomitant activation of GPBAR1 might increase the risk
for adverse side effects.
The activity of BAs towards their receptor counterparts
is structure dependent, with chenodeoxycholic acid (CDCA)
and tauro-lithocholic acid (TLCA), being the most potent
endogenous activators of FXR and GPBAR1 (Figure 1A),
respectively.
In recent years, we have reported the chemical manipulation
on CDCA scaffold, with the aim to improve potency, efficacy
and metabolic stability of endogenous BAs, affording several
hit compounds with promising pharmacological profiles
(Di Leva et al., 2015; Sepe et al., 2016; Finamore et al.,
2016).
In detail, the introduction of an ethyl group at C-6 on
the CDCA afforded to the disclosure of 6-ECDCA/OCA
(Figure 1B)/INT-747 endowed with high potency toward FXR
(Pellicciari et al., 2002). 6-ECDCA has been widely investigated
in in vitro and in vivo (Fiorucci et al., 2011a) and in a phase III
clinical trial in patients with nonalcoholic steatohepatitis (NASH)
(Neuschwander-Tetri et al., 2015). Despite 6-ECDCA improved
several features of NASH, including inflammation and fibrosis,
the above positive findings were tempered by the appearance of
pruritus in 23% of patients and by an increase in total cholesterol
and LDL. In addition, administration in PBC patients caused
pruritus in approx. 50–60% that was severe enough to cause
drug discontinuation in 40% of patients (Mason et al., 2010).
Indeed 6-ECDCA is also a ligand for GPBAR1 (Festa et al.,
2014; Pellicciari et al., 2016; Sepe et al., 2016) and therefore the
above side effect might be associated to the activation of the
membrane BA receptor, recently demonstrated bona fide to be
the physiological mediator of itching in mice (Alemi et al., 2013;
Lieu et al., 2014).
In the present work, we have modified 6-ECDCA scaffold
installing an azido/amino group at the C-3 position. The rationale
for this modification is based on our recent demonstration that
the 3α-OH on BAs forms a stable H-bond with a negatively
charged residue (Glu169) in GPBAR1 (D’Amore et al., 2014;
Di Leva et al., 2015) whereas in FXR-LBD the above functional
group interacts with a positively charged residue (His444).
Therefore, the introduction at C-3 of a polarizable group (dipole)
bearing a partial negative charge on the ligand atom interacting
with the receptor residues, could represent a good strategy to
shift the activity towards FXR. In order to explore further the
chemical space, we manipulated also the side chain and the
configurational assessment of the ethyl group at C-6 and the
hydroxyl group at C-7, producing the small library reported
in the Figure 2. Among this library, optimized compound 2
represents a FXR agonist with a nanomolar potency (EC50 = 846
nM) in transactivation assay and high efficacy in the recruitment
of SRC-1 co-activator peptide in Alfa Screen assay. The above
FIGURE 1 | Endogenous and semisynthetic bile acids as FXR and GPBAR1 agonists. (A) CDCA and TLCA, the endogenous activators of FXR and GPBAR1,
respectively. (B) 6-ECDCA, a semisynthetic dual agonist.
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FIGURE 2 | Chemical library prepared in this study. Modification at C-3, C-6, C-7, and C-24 on 6-ethylcholane scaffold and identification of compound 2 as the
best hit in this series.
potency was accompanied by high selectivity with compound 2
devoid of any activity toward common off-targets such as the
NRs LXRα/β and PPARα/γ and the cell surface G-PCR GPBAR1.
Further, in vivo pharmacological characterization demonstrated
that compound 2 represses BA synthesis in the liver through the
regulation of FXR targeted gene expression. Collectively, these
data, combined with the good pharmacokinetic behavior, affirm
compound 2 as a new therapeutical opportunity for the treatment
of liver FXR-mediated diseases.
MATERIALS AND METHODS
Chemical Material
All reactions were carried out under argon atmosphere
using flame-dried glassware. Solvents and reagents were used
as supplied from commercial sources with the following
exceptions. Hexane, ethyl acetate, chloroform, dichloromethane,
tetrahydrofuran and triethylamine were distilled from calcium
hydride immediately prior to use. Methanol was dried from
magnesium methoxide. Reaction progress was monitored
via thin-layer chromatography (TLC) on Alugram silica
gel G/UV254 plates. Silica gel MN Kieselgel 60 (70–230
mesh) from Macherey–Nagel Company was used for column
chromatography. All chemicals were obtained from Sigma-
Aldrich, Inc. The purity of tested compounds was determined to
be always greater than 95% by analytical HPLC analysis (Waters
Model 510 pump equipped with Waters Rheodine injector
and a differential refractometer, model 401) using a Nucleodur
100-5 C18 Isis (5 µm; 4.6 mm i.d. ×250 mm). High-resolution
ESI-MS spectra were performed with a Micromass Q-TOF mass
spectrometer. NMR spectra were obtained on Varian Inova
400, 500, and 700 NMR spectrometers (1H at 400, 500, and
700 MHz,13C at 100, 125, and 175 MHz, respectively) equipped
with a SUN microsystem ultra5 hardware and recorded in
CD3OD (δH = 3.31 and δC = 49.0 ppm) and CDCl3 (δH = 7.26
and δC = 77.0 ppm). All of the detected signals were in
accordance with the proposed structures. Coupling constants
(J values) are given in Hertz (Hz), and chemical shifts (δ)
are reported in ppm and referred to CHD2OD and CHCl3 as
internal standards. Spin multiplicities are given as s (singlet),
br s (broad singlet), d (doublet), t (triplet), or m (multiplet).
For details on synthetic procedures, see the Supplementary
Material.
Alpha Screen Assay
Activation of FXR was determined by Alpha Screen Technology
in a Coactivator Recruitment Assay. Anti-GST-coated acceptor
beads were used to capture the GST-fusion FXR-LBD, whereas
the biotinylated-SRC-1 peptide was captured by the streptavidin
donor beads. Upon illumination at 680 nm, chemical energy
is transferred from donor to acceptor beads across the
complex streptavidin-donor/SRC-1-biotin/GSTFXR-LBD/anti-
GST-acceptor and a signal is produced. The assay was performed
in white, low-volume, 384-well Optiplates (PerkinElmer) using a
final volume of 25 µL containing final concentrations of 10 nM
of purified GST-tagged FXR-LBD protein, 30 nM biotinylated
SRC-1 peptide, 20 µg/mL anti-GST acceptor beads, and 10
µg/mL of streptavidin donor bead (PerkinElmer). The assay
buffer contained 50 mM Tris (pH 7.4), 50 mM KCl and 1 mM
DTT. The stimulation times with 1 µL of tested compound
(dissolved in 50% DMSO/H2O) were fixed to 30 min at room
temperature. The concentration of DMSO in each well was
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maintained at a final concentration of 2%. After the addition of
the detection mix (acceptor and donor beads), the plates were
incubated in the dark for 3 h at room temperature and then were
read in an Envision microplate analyzer (PerkinElmer).
Transactivations on HepG2 Cells
HepG2 (HB, 8065 from ATCC), an immortalized human
epatocarcinoma cell line, was cultured and maintained at
37◦C and 5% CO2 in E-MEM additioned with 10% FBS, 1%
glutamine, and 1% penicillin/streptomycin. For FXR mediated
transactivation, HepG2 cells were plated at 5 × 104 cells/well
in a 24 well plate. Cells were transfected with 200 ng of the
reporter vector p(hsp27)-TK-LUC containing a FXR response
element (IR1) cloned from the promoter of heat shock protein 27
(hsp27), 100 ng of pSG5-FXR, 100 ng of pSG5-RXR, and 100 ng
of pGL4.70 (Promega), a vector encoding the human Renilla
gene. For GPBAR1 mediated transactivation, HepG2 cells were
plated at 5 × 104 cells/well in a 24 well-plate and transfected
with 200 ng of pGL4.29 (Promega), a reporter vector containing
a cAMP response element (CRE) that drives the transcription of
the luciferase reporter gene luc2P, with 100 ng of pCMVSPORT6-
human GPBAR1, and with 100 ng of pGL4.70 Renilla. In both
assays, at 24 h post-transfection, cells were stimulated 18 h with
compounds 1–16 (1 and 10 µM). 6-ECDCA (1 and 10 µM) was
used as a positive control for FXR activity. TLCA (10 µM) was
used as a positive control for GPBAR1 activity.
In vitro Selectivity of Compound 2
To evaluate LXRα and LXRβ mediated transactivation, HepG2
cells were transfected with 200 ng of the reporter vector
p(UAS)5XTKLuc, 100 ng of a vector containing the ligand
binding domain of LXRα or LXRβ cloned upstream of the
GAL4-DNA binding domain (i.e., pSG5-LXRαLBD-GAL4DBD
or pSG5-LXRβLBD-GAL4DBD) and 100 of pGL4.70 Renilla.
At 24 h post-transfection, cells were stimulated 18 h with
10 µM compound 2 and GW3965 (GW, 10 µM) was used as
positive control. To investigate the PPARα and PPARγ mediated
transactivation, HepG2 cells were transiently transfected with
200 ng reporter vector p(UAS)9XTKLuc, 100 ng of a vector
containing the ligand binding domain of PPARα or PPARγ
cloned upstream of the GAL4-DNA binding domain (i.e., pSG5-
PPARαLBD-GAL4DBD or pSG5- PPARγLBD-GAL4DBD) and
100 of pGL4.70 Renilla. For PPARα transactivation, cells
were stimulated with 10 µM compound 2 and gemfibrozil
(GEM, 10 µM) was used as positive control. For PPARγ
transactivation, cells were stimulated with 10 µM compound 2
and rosiglitazone (ROSI, 100 nM) was used as a positive control.
Luciferase activities were assayed and normalized with Renilla
activities.
Dose-Response Curve for Compound 2
and Its Tauro-Conjugate 2a on FXR
HepG2 cells were transfected as described above and then
treated with increasing concentrations of compounds. At 18 h
post stimulations, cellular lysates were assayed for luciferase
and Renilla activities using the Dual-Luciferase Reporter assay
system (E1980, Promega). Luminescence was measured using
Glomax 20/20 luminometer (Promega). Luciferase activities were
normalized with Renilla activities.
RNA Isolation and RT-PCR
HepG2 cells were plated at 1 × 106 cells/well in a six well
plate. After an overnight incubation, cells were starved and
then stimulated for 18 h with compound 2 at 1 µM. Total
RNA was isolated from HepG2 cells or liver tissues using the
TRIzol reagent according to the manufacturer’s specifications
(Invitrogen). One microgram of purified RNA was treated with
DNase-I and reverse transcribed with Superscript II (Invitrogen).
For Real Time PCR, 10 ng template was dissolved in 25 µL
containing 200 nmol/L of each primer and 12.5 µL of 2× SYBR
FAST Universal ready mix (Invitrogen). All reactions were
performed in triplicate, and the thermal cycling conditions were
as follows: 2 min at 95◦C, followed by 40 cycles of 95◦C for 20 s
and 60◦C for 30 s in StepOnePlus (Applied Biosystems). The
relative mRNA expression was calculated accordingly to the Ct
method. Primers were designed using the software PRIMER31
using published data obtained from the NCBI database. Forward
and reverse primer sequences were the following: human
GAPDH, gaaggtgaaggtcggagt and catgggtggaatcatattggaa; human
BSEP, gggccattacgagatccta and tgcaccgtcttttcactttctg; human
OSTα, tgttgggccctttccaatac and ggctcccatgttctgctcac; human
SHP, tctcttcttccgccctatca and aagggcttgctggacagtta; mouse NTCP,
ggtgccctacaaaggcatta and gttgcccacattgatgacag; mouse CYP7A1,
aagccatgatgcaaaacctc and gccggaaatacttggtcaaa; mouse FGF21,
acacagatgacgaccaagacac and aagtgaggcgatccatagagag; mouse
GAPDH, ctgagtatgtcgtggagtctac and gttggtggtgcaggatgcattg;
mouse BSEP, atgcttgtgaccctgcaaa and agatcgttgacggatggaag;
mouse OSTα, ctttggtgggaagaaagcag and gaagaaggcgtactggaaagg;
mouse SHP, tctcttcttccgccctatca and aagggcttgctggacagtta.
Animal
C57BL6 male mice were from Harlan Nossan (Udine, Italy). The
colonies were maintained in the animal facility of University
of Perugia. Mice were housed under controlled temperatures
(22 ◦C) and photoperiods (12:12-hour light/dark cycle), allowed
unrestricted access to standard mouse chow and tap water and
allowed to acclimate to these conditions for at least 5 days
before inclusion in an experiment. A total number of eight mice
were used in this study. The study was conducted in agreement
with the Italian law and the protocol was approved by Ethical
Committee of University of Perugia and by a National Committee
of Ministry of Health (permission N◦ 42/2014 B). The health
and body conditions of the animals were monitored daily by
the veterinarian in the animal facility. At the day of sacrifice
mice were deeply anesthetized with a mixture of tiletamine
hypochlorite and zolazepam hypochlorite/xylazine at a dose of
50 mg/Kg.
Animal Models
C57BL6 male mice (8) were administered with compound 2
(50 mg/Kg body weight per os) or vehicle (distilled water) for
1http://frodo.wi.mit.edu/primer3/
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3 days. At the day of sacrifice livers, gallbladders, blood and feces
were collected from mice for further analysis.
Bile Acid Determinations
Bile acids pools were measured by liquid chromatography-
tandem mass spectrometry (MS/MS) analysis, using
chromatographic conditions as described elsewhere (John
et al., 2014). The stock solutions of the individual tauro-
conjugated and un-conjugated BAs were prepared separately in
methanol at a concentration of 1 mg/mL. All stock solutions
were stored at –20◦C. Calibration standards were prepared by
combining appropriate volumes of each BA stock solution and
methanol. The calibration range was from 10 nM to 100 µM
of each BA in the final solution. Mice serum sample aliquots of
20 µL were mixed with 80 µL of CH3OH, shaken continuously,
vortexed and, after centrifugation at 16000 g for 10 min, the
clear supernatant was transferred to a new vial, snap frozen
and lyophilized. The sample was then re-dissolved in 40%
water/ 60% MeOH with 0.1% formic acid and ammonium
acetate 5 mM. A BA extraction yield of 95% has been measured
using BA standard addition in plasma sample before and after
deproteinization procedure. For gallbladder, 10 mg of lyophilized
gallbladder were manually pestle using a mortar and dissolved in
1 mL CH3OH. After centrifugation at 16000 g for 10 min, 500 µL
of supernatants were lyophilized and reconstituted in 100 µL of
40% water/60% MeOH with 0.1% formic acid and ammonium
acetate 5 mM.
Liquid Chromatography and Mass
Spectrometry
For LC-MS/MS analysis, chromatographic separation was carried
out on the HPLC-MS system Q-TRAP 6500 LC-MS/MS System
from AB Sciex equipped with Shimadzu LC-20A LC and
AutoSampler system. The mixture was separated on a Synergi
Fusion RP 4 m from Phenomenex (150 mm× 2.00 mm).
Tauro-conjugated and non-conjugated BAs were separated
at a flow rate of 200 µL/min using a methanol–aqueous
ammonium acetate (NH4OAc) gradient. Mobile phase A was
water containing 5 mM ammonium acetate and 0.1% formic acid,
mobile phase B was methanol, containing ammonium acetate at
5 mM and 0.1% formic acid. The gradient started at 65% B and
increased to 85% B in 23 min, kept at 85% B for 5 min then
decreased to 65% B in 1 min and kept at 65% B for 10 min. ESI was
performed in negative ion mode and the ion source temperature
was set at 280◦C. The tune page parameters were automatically
optimized injecting taurocholic acid at 1 µM as standard. The
MS/MS detection was operated in MRM mode using a collision
energy of 20 (arbitrary units) and the observed transitions are
reported in Mencarelli et al., 2013.
Molecular Modeling
In order to investigate ligand interaction with FXR-LBD, we
performed docking calculations that are very widely used to
generate and rank binding complexes based on empirical scoring
functions (Anzini et al., 2008, 2011; Heckmann et al., 2009;
Cerqueira et al., 2015). In the present case, we used the Glide
(version 7.1) (Schrödinger, 2016a) software package to perform
molecular docking calculations in the crystal structure of the
FXR-LBD from Rattus norvegicus (rFXR) in complex with 6-
ECDCA and the GRIP-1 coactivator peptide NID-3 (PDB code
1osv) (Mi et al., 2003). rFXR-LBD shares indeed the 95% of
homology with that of the human FXR-LBD (hFXR-LBD), with
all of the residues in the ligand binding pocket conserved
among the two species. Protein structure was prepared as
described in a previous paper (Di Leva et al., 2013). Ligand
tridimensional structures were generated with the Maestro
build panel (Schrödinger, 2016c). For each ligand, an extensive
ring conformational sampling was performed with MacroModel
(version 11.3) (Schrödinger, 2016d) using the OPLS3 force field
(Harder et al., 2016) and a 2.0 Å rmsd cutoff for clustering.
All conformers were then refined using LigPrep (Schrödinger,
2016b) as implemented in Maestro. Protonation states at pH
7.4 were assigned using Epik (Shelley et al., 2007; Greenwood
et al., 2010). In Glide, a box of 25 Å × 25 Å × 25 Å centered
on the FXR binding cavity was initially created to compute the
interaction grids. Upon docking calculations, ligands macrocyclic
rings were treated as rigid; otherwise, default parameters were
applied. The standard precision (SP) mode of the GlideScore
function was used to score and rank the predicted binding poses
(Friesner et al., 2004; Halgren et al., 2004). For each ligand, the
best 10 docking poses were considered for visual inspection. All
the residue labels were taken from the aforementioned crystal
structure of rFXR-LBD.
Statistical Analysis
Statistical analysis was performed with Prism 6.0 software
(GraphPad). The non parametric Mann–Whitney U test or
a 2-tailed unpaired Student t-test was used for statistical
comparisons (∗P < 0.05, ∗∗P < 0.005, ∗∗∗P < 0.0005).
RESULTS
Chemistry
Our planned strategy started from methyl 6β-ethyl-7-
ketocholanoate 17 (Figure 3), which was prepared following our
previously described procedure (Festa et al., 2014). Mesylation
at C-3 and subsequent treatment with NaN3 furnished the
3β-azido derivative 18 as a cornerstone intermediate in the
preparation of derivatives 1–4. First, inversion at C-6 with
NaOMe/MeOH treatment followed by concomitant reduction
at C-7 carbonyl group and at C-24 methyl ester furnished 3.
Basic treatment (NaOH, MeOH/H2O) on 18 proceeded in a
straightforward manner affording the concomitant hydrolysis
on the side chain methyl ester and inversion at C-6 ethyl group
producing 1, that in a small amount was reduced affording the
corresponding 7α-hydroxy derivative, compound 2, in 98%
yield after purification. Finally, hydride reduction of 18 afforded
pure 4.
The counterpart 3α-azido derivatives 5–8 were prepared
following the synthetic protocol depicted in Figure 3.
Tosylation at C-3 hydroxyl group on methyl ester 17 followed
by inversion of configuration afforded the 3β-hydroxy derivative
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FIGURE 3 | Preparation of chemical library. Reagent and conditions: (a) MsCl, TEA; ethyl ether, –10◦C; (b) NaN3, DMSO, DMF, 150◦C; (c) NaOMe, MeOH, r.t.;
(d) LiBH4, MeOH dry, THF, 0◦C; (e) NH4Cl, Zn, MeOH:H2O (1:0.1); (f) NaOH 5% in MeOH/H2O 1:1 v/v, reflux; (g) pTsCl, pyridine, r.t.; (h) CH3COOK, DMF:H2O (5:1),
reflux.
19, which was in turn transformed in the corresponding
3α-azido derivative 20 in the same operative conditions
reported for 18 (Figure 3). Elaboration of the functional
groups on ring B and on the side chain following the
same synthetic protocol of the corresponding 3β-azido
derivatives afforded compounds 5–8 in good chemical yield.
Finally, by reduction of the azido group of the resulting
derivatives 1–8 with zinc powder (Lin et al., 2002), the
required 3β- and 3α-amino derivatives 9–16 were available
(Figure 3).
Cell-Free Alpha Screen Assay on the
Whole Library
Potency and efficacy of compounds 1–16 were firstly evaluated
on FXR in a cell-free Alpha Screen assay in comparison with 6-
ECDCA (Table 1).
In this assay, compound 2 shows a potent activity and high
efficacy in the recruitment of SRC-1 peptide, as evidenced by
its nanomolar potency at FXR (EC50 610 nM, 90% efficacy
respect to 6-ECDCA). Of interest, the above activity decreases
with the modification of the configuration at C-3 (compare
2 with the corresponding 3α-azido 6 in Table 1) as well as
with the introduction of an alcoholic function as side chain
end group (compare 2 vs. 3 and 6 vs. 7 in Table 1). As
expected (Festa et al., 2014), in this subset the configurations
at C-6/C-7 as well as the presence of a hydroxyl group at C-
7 profoundly affect FXR activation with compounds 1, 4, 5,
and 8 showing a remarkable reduction in term of efficacy in
the recruitment of SRC-1 co-activator peptide in Alfa Screen
assay. Finally, the corresponding 3-amino derivatives 9–16 did
not show any effect in the recruitment assay in the concentration
range 20 nM–20 mM.
TABLE 1 | FXR activities of compounds 1–16 measured as recruitment of
SRC-1 co-activator peptide in Alfa Screen assaya.
Compound EC50 Efficacy
6-ECDCAb 0.12 ± 0.01 100
1 32
2 0.61 ± 0.09 90
3 0.55 ± 0.08 55
4 39
5 24
6 1.38 ± 0.35 61
7 1.80 ± 0.21 57
8 49
9 n.d. n.d.
10 n.d. n.d.
11 n.d. n.d.
12 n.d. n.d.
14 n.d. n.d.
15 n.d. n.d.
16 n.d. n.d.
aData represent mean values ± SD of three different experiments.
Units are µM for EC50. Efficacy is calculated as % of the effect in the recruitment
respect to 6-ECDCA at 2 µM.
EC50 has been reported for efficacy ≥50%; n.d. = non-detectable up to 20 µM
b6-ECDCA was prepared as previously reported (Finamore et al., 2016).
Transactivation Assay on HepG2 Cells
Transiently Transfected with hFXR
The above results were substantially confirmed in a
transactivation assay on HepG2 cells transiently transfected
with hFXR (Figure 4A). As reference compound, 6-ECDCA was
used in concentrations of 1 and 10 µM. The best results were
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FIGURE 4 | In vitro screening on the library. (A) FXR transactivation on HepG2 cells. HepG2 cells were transfected with pSG5-FXR, pSG5-RXR,
PGL4.70-Renilla, and p(hsp27) TKLUC vectors. Cells were stimulated with compounds 1–16 (1 and 10 µM). 6-ECDCA (6E, 1 and 10 µM) was used as positive
control. (B) GPBAR1 transactivation on HepG2 cells. HepG2 cells were co-transfected with GPBAR1 and a reporter gene containing a cAMP responsive element in
front of the luciferase gene. Cells were stimulated with 6-ECDCA (6E, 1 µM) and compounds 1–16 (1 and 10 µM). TLCA (10 µM) was used as positive control.
Luciferase activity served as a measure of the rise in intracellular cAMP following activation of GPBAR1. In both panels, results are expressed as mean ± standard
error. ∗p < 0.05 versus not treated cells (NT).
obtained with compound 2, which turned out to be equipotent
with 6-ECDCA at 10 µM, followed, in order of efficacy at 10 µM,
by its 3α-epimer, compound 6, and the corresponding C-24
alcohol, compound 3.
Transactivation Assay on HepG2 Cells
Transiently Transfected with GPBAR1
Of interest, results of transactivation of CREB-responsive
elements in HepG2 cells, transiently transfected with the
membrane BA receptor GPBAR1 (Figure 4B), clearly
showed that 6-ECDCA is endowed with GPBAR1 agonism
at 1 µM whereas the introduction of an azido group at C-3
(compounds 1–8) is detrimental for GPBAR1 activation.
Among the corresponding 3-amino derivatives (compounds
9–16), compounds 11, 13, and 14, even if less potent
than TLCA, the endogenous GPBAR1 agonist, showed
a residual activity toward the membrane BA receptor.
This result is in agreement with our computation model
of GPBAR1 (D’Amore et al., 2014) and with our recent
observation that the replacement of the 3α-OH on LCA
scaffold with a positively charged group should lead to
a selective GPBAR1 activation over FXR (Di Leva et al.,
2015).
Computational Studies
Docking calculations, performed using the software GLIDE
(Schrödinger, 2016a), allowed the rationalization of the above
activities. In particular, the most active compound of the series,
compound 2, was docked in the crystal structure of the FXR
ligand binding domain (FXR-LDB) (PDB code 1osv) (Mi et al.,
2003) where the binding site is shaped by five alpha-helices H3,
H5, H7, H11, and H12. In the best docking pose, the steroidal
scaffold of 2 establishes favorable hydrophobic interactions with
the side chains of Leu284, Met287, Ala288, Met325, and Leu345,
Frontiers in Pharmacology | www.frontiersin.org 7 March 2017 | Volume 8 | Article 162
fphar-08-00162 March 29, 2017 Time: 16:30 # 8
Festa et al. A Novel FXR Agonists in Liver Diseases
FIGURE 5 | Docking analysis on compound 2 and 6-ECDCA in FXR ligand binding domain. (A) Binding mode of compound 2 in the FXR-LBD. The ligand is
depicted as cyan sticks, while FXR is shown as orange (helices H3, H4, and H12) and gray cartoons. Amino acids important for ligand binding are shown as orange
sticks. Hydrogens are omitted for clarity. (B) Superposition between the predicted binding mode pose of 2 and the crystallographic pose of 6-ECDCA (yellow sticks).
while the ligand carboxylate group forms a salt bridge with
Arg328 (Figure 5A). The presence of the latter interaction might
play a key role in the activation of the receptor as previously
suggested in literature (Mi et al., 2003). On the other side,
the 3β-azido moiety of 2 engages H-bond interactions with
Tyr358 on H7 and His444 on H11. The latter H-bond allows the
stabilization of the cation-pi interaction formed by His444 and
Trp466 on H12, which is crucial to lock FXR in the conformation
competent for the recruitment of coactivator peptides and the
activation of the transcription of target genes (Mi et al., 2003;
Di Leva et al., 2013). Finally, the ligand 7α-OH group forms
H-bonds with the Ser329 and the Tyr366 hydroxyl groups,
while the 6α-ethyl substituent engages hydrophobic contacts with
Tyr358, Ile359, and Phe363, which altogether further stabilize
the ligand binding mode. It is also interesting to note that the
docking pose of 2 is highly superimposable (Figure 5B) with that
experimentally found for 6-ECDCA (Mi et al., 2003). Although
the configuration of the azido compound is beta at C-3, hence
inverted if compared to 6-ECDCA, the geometry of the azido
group allows, however, the proper orientation of the ligand in the
LBD, pointing towards His444. Furthermore, the dipole moment
of the azido group charges negatively the distal nitrogen atom at
C-3, thus stabilizing the interaction with the positively charged
His444.
Docking simulations on compounds 3, 6 and 7 (see Figure S1
in the Supporting Information) revealed that alcohol derivatives
3 and 7 binds FXR similarly to the carboxylic analogs 2 and 6,
albeit establishing weaker interactions with Arg328. Thus, a polar
uncharged group on the BA side chain is tolerated, however the
related compounds might show a decreased activity. On the other
hand, the oxidation of the 7α-OH group (1) and the inversion of
configuration at C-6 and C-7 (4) weaken the H-bond interactions
with Ser329 and Tyr366 and might generate steric clash with
the protein residues, leading to less potent analogs. Similarly,
the inversion of configuration at C-3 changes the geometry of
the H-bond interactions formed by the azido group with the
Tyr358 and His444 side chains, weakening the ligand/receptor
interaction and thus explaining loss in efficacy shown by the 3α
derivatives 5–8 compared to the 3β analogs 1–4. Finally, in line
with our previous findings (Di Leva et al., 2015), the presence of
a protonable primary amine at C-3, such as in derivatives 9–16,
is not tolerated due to repulsive electrostatic interactions with the
positively charged His444, thus explaining why these compounds
are inactive towards FXR.
Further Pharmacological
Characterization of Compound 2, the
Best Hit Generated in this Study
Compound 2 Transactivates FXR in a
Dose-Dependent Manner
The relative potency of compound 2 was first investigated by
a detailed measurement of concentration-response curve in
transactivation assay on HepG2 cells. As illustrated in Figure 6A,
compound 2 transactivates FXR with an EC50 of 846 nM.
Compound 2 Modulates FXR Target Gene Expression
in HepG2 Cells
Further, the effect of 2 in modulating FXR target genes was
assessed in liver carcinoma cell line HepG2 by RT-PCR, with 6-
ECDCA (1 µM) and CDCA (10 µM) as reference compounds.
As showed in Figures 6B–D, compound 2 at 1 µM concentration
resulted more potent than 6-ECDCA in modulating OSTα
and BSEP expression and equipotent with 6-ECDCA in the
modulation of SHP mRNA expression. Because these three genes
are endowed with canonical FXR-responsive elements in their
promoter, their induction is fully consistent with the nature of
compound 2 as potent FXR agonist.
Compound 2 is a Selective FXR Agonist
To characterize the pharmacological profile of 2, we also
investigated the activity on common off-targets. As showed in
Figure 7, compound 2 (10 µM) was unable in inducing PPARα
and PPARγ as well as LXRα and LXRβ transactivation on HepG2
cells. Further, Figure 7C confirmed the inactivity of 2 toward
GPBAR1 at 50 and 100 µM concentrations.
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FIGURE 6 | Compound 2, the best hit generated in this study. In vitro evaluation on FXR activity. (A) FXR activity was measured in HepG2 cells co-transfected
with pSG5-FXR, pSG5-RXR, PGL4.70-Renilla, and p(hsp27)TKLUC vectors. Twenty-four hours post transfection cells were stimulated with increasing
concentrations of 2 from 10 nM to 25 µM. Results are expressed as mean ± standard error. (B–D) RT-PCR analysis of mRNA expression on FXR target genes SHP
(B), OSTα (C) and BSEP (D) in HepG2 cells primed with 2 (1 µM). CDCA (10 µM) and 6-ECDCA (1 µM) were used as positive controls. Values are normalized to
GAPDH and are expressed relative to those of not treated cells (NT) which are arbitrarily settled to 1. The relative mRNA expression is expressed as 2(−11Ct).
∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.0005 versus not treated cells (NT).
FIGURE 7 | Target selectivity of compound 2. (A) HepG2 cells were transiently transfected with p(UAS)9XTKLuc, pSG5-PPARα-LBD-GAL4DBD or pSG5-
PPARγ LBD-GAL4DBD and pGL4.70 Renilla vectors. Cells were stimulated with gemfibrozil (GEM, 10 µM) and rosiglitazone (ROSI, 100 nM), as positive controls for
PPARα and PPARγ, respectively, and compound 2 (10 µM). (B) HepG2 cells were transfected with p(UAS)5XTKLuc, pSG5-LXRα LBD-GAL4DBD or pSG5-LXRβ
LBD-GAL4DBD and pGL4.70 Renilla vectors. Cells were stimulated with GW3965 (GW, 10 µM) as positive control and compound 2 (10 µM). (C) HepG2 cells were
co-transfected with GPBAR1 and a reporter gene containing a cAMP responsive element in front of the luciferase gene. Cells were stimulated with 2 (50 and
100 µM). TLCA (10 µM) was used as positive control. Luciferase activity served as a measure of the rise in intracellular cAMP following activation of GPBAR1. In all
panels, results are expressed as mean ± standard error. ∗p < 0.05 versus not treated cells (NT).
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FIGURE 8 | In vivo evaluation of compound 2 effect on FXR target gene expression. C57BL6 mice were treated for 3 days with compound 2 (50 mg/kg per
os). The relative hepatic mRNA expression of FXR target genes BSEP, OSTα, SHP, CYP7A1, NTCP, and FGF21 was assayed by RT-PCR. Results are the
mean ± SE of 3–5 mice per group. ∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.0005 versus naive mice (Control).
Compound 2 Affects Gene Expression in C57BL6
Mice
Further investigating its pharmacological properties, compound
2 was administered (50 mg/kg, os) to C57BL6 mice. At 6 days
post-treatment, livers were collected. As shown in Figure 8,
compound 2 significantly up-regulated the relative mRNA
expression of canonical FXR molecular targets such as BSEP,
OSTα, SHP, and FGF21 and downregulated CYP7A1 in the liver
(∗p < 0.05 versus control mice), thus confirmed RT-PCR data on
HepG2 cells (Figures 6B–D).
Compound 2 Affects BA Pool in C57BL6 Mice
Analysis of unconjugated and tauro-conjugated BA
concentrations and evaluation of metabolite profile of 2 after oral
FIGURE 9 | Effects of compound 2 after mice administration on bile acid pool and evaluation of metabolic profile. (A–C) Effects of compound 2
administration on levels of unconjugated and tauro-conjugated bile acids in plasma (A,B, respectively) and gallbladder (C). (D,E) Plasmatic and gallbladder levels of
2 and 2a. Results are the mean ± SE of 5 mice per group. ∗p < 0.05 versus naive mice, #p < 0.05 versus 2 treated mice. (F) Preparation of compound 2a. (G) In
vitro evaluation of 2a on FXR. Activity was measured in HepG2 cells co-transfected with pSG5-FXR, pSG5-RXR, pGL4.70 Renilla and p(hsp27) TKLUC vectors.
Twenty-four hours post transfection cells were stimulated with increasing concentrations of 2a from 10 nM to 25 µM. Results are expressed as mean ± standard
error.
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administration of compound 2 at 50 mg/kg in C57BL6 mice
was performed by LC-MS. As showed in Figures 9B,C,
in vivo administration of 2 significantly reduced plasmatic
and gallbladder levels of tauro-cholic acid (tCA) and tauro-
muricholic acid (tMu), two primary BAs in mouse. The
reduction of tCA concentration, together with the reduction
of the corresponding secondary BA, tauro-deoxycholic acid
(tDCA), is consistent with FXR agonistic profile of compound 2
and the consequent downregulation of hepatic enzymes involved
in BA synthesis, such as cytochrome P450 7A1 (CYP7A1).
In vivo Metabolic Profile of Compound 2
Evaluation of the pharmacokinetic and metabolite profiles of
compound 2 first required the preparation of the corresponding
tauro-conjugate derivative 2a through amidation with taurine
followed by HPLC purification (Figure 9F). LC-MS analysis
demonstrated a large grade of tauro-conjugation in the liver
with compound 2a efficiently recovered in bile and in
plasma (Figures 9D,E). Transactivation assay demonstrated the
preserved dose dependent agonistic activity on FXR with an
EC50 value in micromolar range and comparable to that of
free carboxylic acid 2 (Figure 9G). Because endogenous BAs
and semisynthetic BA derivatives are extensively conjugated in
the liver (tauro-conjugation in mice and glyco-conjugation in
human), this result highlights the therapeutical potential of 2 in
human FXR mediated diseases.
DISCUSSION
FXR is a BA sensor. In hepatocytes, a rise in intracellular BA
concentrations results in the transcriptional activation of FXR.
One FXR target gene is the small heterodimer partner (SHP),
whose transcriptional activation results in a decrease in CYP7A1,
the key enzyme in BA synthesis, gene expression and therefore
in the inhibition of BA synthesis through the neutral pathway
(Wang et al., 2002).
In this paper, we report the generation of BA derivatives
characterized by the installation of an azido/amino group at
the C-3 position of 6-ethylcholane scaffold. A member of this
family of compounds, and namely compound 2, appears to be
specific for FXR and does not activate other NRs including LXRα
and β and PPARα and γ. Compound 2 is endowed with potent
activity toward FXR in cell free assay (EC50 610 nM) and in
transactivation assay on HepG2 cells (EC50 846 nM), while the
compound is essentially devoid of any activity toward GPBAR1.
The in vitro characterization of compound 2 in HepG2 cells
demonstrated that this agent exerts FXR agonistic activity and
increases the expression of three canonical FXR targeted genes,
such as SHP, OSTα and BSEP. As pointed before, SHP is an
orphan NR that lacks a DNA binding domain and plays an
essential role in FXR signaling in target cells. SHP functions
as a co-repressor for CYP7A1 leading to a robust inhibition
of the synthesis of endogenous BAs in the liver. Although a
SHP-independent mechanism exists that negatively regulates BA
synthesis, in the context of FXR signaling, induction of SHP
represents a robust measure of FXR activation. Indeed, all three
genes shown in this study to be regulated by compound 2, are
directly modulated by FXR through its binding to canonical
FXR-responsive elements in their promoter.
The fact that compound 2 behaves as FXR ligand was
confirmed in vivo. Indeed, administration of compound 2 to
mice resulted in a profound reshaping in the expression of
FXR target genes in the liver. The results shown in Figure 8
demonstrate that compound 2 when fed to mice at the dose
of 50 mg/kg increases the expression of BSEP, OSTα and SHP
mRNAs while represses the gene expression of CYP7A1. Taken
together these data are consistent with concept that compound 2
activates FXR and represses the synthesis of endogenous BAs. In
addition, compound 2 increases the gene expression of FGF21.
Because, FGF21 is thought to act in an autocrine fashion by
binding to the FGF receptor 4 and regulating BA synthesis
via repression of CYP7A1 gene expression, these data strongly
indicate that compound 2 is a robust inhibitor of the synthesis
of endogenous BAs (Kliewer and Mangelsdorf, 2015). This view
is strongly supported by results shown in Figures 9A–C. Indeed,
administering mice with compound 2 effectively reduced the level
of tauro-conjugated BAs in the blood and gallbladder. The blood
levels of three primary BAs, i.e., tCA, tMu, and tHCA, were
significantly reduced by treating mice with compound 2 at the
dose of 50 mg/kg. These findings were completely consistent with
the repression of CYP7A1 gene expression in the liver. These data
were also confirmed by examining the relative concentrations of
the above tauro-conjugated primary BAs in the gallbladder.
The preliminary characterization of in vivo pharmacokinetic
properties of compound 2 revealed that this compound
undergoes an extensive liver metabolism (Figures 9D,E). Thus,
while compound 2 is partially excreted as intact molecule in
the bile and could be found in the gallbladder and blood, we
observed that this compound is mostly disposed by the liver as a
tauro-conjugate. Importantly, the tauro-derivative of compound
2, i.e., compound 2a, maintains a full agonist activity toward FXR
(Figure 9G).
FXR ligands have been exploited in recent years in the
treatment of a variety of human diseases (Fiorucci and Baldelli,
2009; Fiorucci et al., 2011b, 2012a,b, 2014; Fiorucci, 2012;
Sepe et al., 2015a). The most extensive characterization has
been in the treatment of PBC and steatohepatitis. Despite the
prototype of this class, 6-ethylCDCA (6-ECDCA) also known as
obeticholic acid, has shown some effectiveness in the treatment
of these conditions, the severity of itching represents a significant
limitation to its use. A proportion of approximately 50–60%
of PBC patients (Mason et al., 2010) and 23% of patients with
NASH (Neuschwander-Tetri et al., 2015) develop itching when
treated with obeticholic acid. While the reason for this effect has
not been elucidated, there is evidence that it could be linked to
the activation of GPBAR1 (Festa et al., 2014; Pellicciari et al.,
2016; Sepe et al., 2016), which is considered an itching receptor
(Alemi et al., 2013; Lieu et al., 2014). Thus, development of highly
selective FXR ligands might help to overcome this limitation.
In summary, we have discovered a novel family of selective
FXR ligands that regulate the expression of FXR target genes in
the liver and repress BA synthesis. These compounds might hold
utility in the treatment of FXR-mediated diseases.
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